Sight Sciences, Inc. (SGHT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...
Sight Sciences continues to navigate significant reimbursement challenges, limiting revenue growth despite strong clinical evidence for its glaucoma and dry eye treatments. Recent headcount reductions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results